Skip to main content
Fig. 10 | Journal of Neuroinflammation

Fig. 10

From: The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke

Fig. 10

Ex-4 inhibits VEGF-A expression in astrocytes via JAK2/STAT3 signaling. a Representative western blots showing the levels of p-JAK2, p-STAT3, and HIF-1α in astrocytes cultured under different conditions. Total JAK2, total STAT3, and GADPH were used as the loading controls. b Quantitative analyses of p-JAK2, p-STAT3, and HIF-1α levels. The data are presented as the mean ± SD (n = 6). c Representative western blots showing the levels of p-JAK2, p-STAT3, and VEGF-A in astrocytes cultured under different conditions. Total JAK2, total STAT3, and GADPH were used as the loading controls. d Quantitative analyses of p-JAK2, p-STAT3, and VEGF levels. The data are presented as mean ± SD (n = 6). e Representative western blots for p-JAK2 and p-STAT3 expressions in different models, and total JAK2, total STAT3, and GADPH were used as the loading controls. f Quantitative analyses of p-JAK2 and p-STAT3 levels. The data are presented as the mean ± SD (n = 6). Medium, cultured with normal medium; Ex4, treated with Ex-4 for 24 h; OGD+RO, treated with OGD for 4 h plus RO for 24 h; OGD+RO+Ex4, treated with OGD for 4 h plus RO for 24 h in the presence of Ex-4; OGD+RO+AG490, treated with OGD for 4 h plus RO for 24 h with a preincubation with AG490. *P < 0.05 compared with the Medium group, #P < 0.05 compared with the Ex4 group, $P < 0.05 compared with the OGD+RO group in Fig. 10b; *P < 0.05 compared with the Medium group, and #P < 0.05 compared with the OGD+RO group in Fig. 10d; *P < 0.05 compared with the Sham group, #P < 0.05 compared with the MCAO group in Fig. 10e, ANOVA plus SNK test (b, d, e)

Back to article page